Trial reportEuropean journal of nuclear medicine and molecular imaging2010
18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation.
Trial report in European journal of nuclear medicine and molecular imaging, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Diagnostic accuracy ofThe British journal of radiology · 2018Pooled it
- Recommendations for the management of adrenal incidentalomas: what is pertinent for radiologists?The British journal of radiology · 2017Guideline
- Current generation time-of-flight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands.Annals of nuclear medicine · 2016Trial
- Surgery for advanced adrenal malignant disease: recommendations based on European Society of Endocrine Surgeons consensus meeting.The British journal of surgery · 2024Article
- Adrenal malakoplakia a rare lesion that mimics a neoplasm.Urology case reports · 2023Article
- Alterations inMolecular imaging and radionuclide therapy · 2023Article
- Adrenal findings in FDG-PET: analysis of a cohort of 1021 patients from a cancer center.Hormones (Athens, Greece) · 2023Article
- Role ofReports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2023Article
- 18F-FDG PET/CT image findings of a dog with adrenocortical carcinoma.BMC veterinary research · 2022Article
- Review
- 18F-FDG-PET/CT Evaluation of Indeterminate Adrenal Masses in Noncancer Patients.The Journal of clinical endocrinology and metabolism · 2021Article
- May an adrenal incidentaloma change its nature?Journal of endocrinological investigation · 2020Article
- Usefulness of FDG-PET/CT-Based Radiomics for the Characterization and Genetic Orientation of Pheochromocytomas Before Surgery.Cancers · 2020Article
- FDG PET/CT in the Staging of Lung Cancer.Current radiopharmaceuticals · 2020Review
- Clinical analysis of adrenal lesions larger than 5 cm in diameter (an analysis of 251 cases).World journal of surgical oncology · 2019Article
- Diagnostic efficacy of 18F-FDG PET/CT in patients with adrenal incidentaloma.Endocrine connections · 2019Article
- Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives.European journal of nuclear medicine and molecular imaging · 2018Review
- Clinical Guidelines for the Management of Adrenal Incidentaloma.Endocrinology and metabolism (Seoul, Korea) · 2017Review
- 5th International ACC Symposium: Imaging for Diagnosis and Surveillance of Adrenal Tumors--New Advances and Reviews of Old Concepts.Hormones & cancer · 2016Review
- What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?European journal of nuclear medicine and molecular imaging · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis prospective multicentre study assesses the usefulness of FDG PET/CT in characterizing and making the therapeutic decision concerning adrenal tumours that are suspicious or indeterminate in nature after conventional examinations (CE).
methodsSeventy-eight patients (37 men, 41 women, 81 adrenal lesions) underwent FDG PET/CT after CE including CT scan, biological tests and optionally (131)I-metaiodobenzylguanidine (MIBG) and/or (131)I-norcholesterol scans. FDG adrenal uptake exceeding that of the liver was considered positive. PET results were not decisive. Surgery was discussed when at least one of the following criteria was found during CE: size >3 cm, spontaneous attenuation value >10 HU, heterogeneous aspect, abnormal MIBG or norcholesterol scan or hormonal hypersecretion.
resultsFollowing the gold standard (histology analysis or >or=9 months follow-up), 49 lesions potentially qualified for surgery (malignant = 27, benign secreting = 22) and 32 benign non-secreting lesions did not. PET was negative in 97% of non-surgical lesions and positive in 73% of potentially surgical ones which included all the malignant lesions, except 3 renal cell metastases, and 12 of 22 benign secreting lesions. The negative predictive value for malignancy was 93% (41/44) and positive predictive value for detecting surgical lesions was 97% (36/37). A high FDG uptake (maximum standardized uptake value >or= 10) was highly predictive of malignancy.
conclusionAdrenal FDG uptake is a good indicator of malignancy and/or of secreting lesions and should lead one to discuss surgery. If there is no prior history of poorly FDG-avid cancer, the absence of FDG uptake should avoid unnecessary removal of benign adrenal lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.